COMMUNIQUÉS West-GlobeNewswire

XORTX Welcomes New Member to the Board of Directors
08/04/2024
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on [...]
World Orphan Drug Alliance Expands to Japan & South Korea and the African Subcontinent
08/04/2024
Japan, South Korea, and the African subcontinent are now covered by the Alliance. With the addition of two new WODA members – Nxera Pharma (formerly Sosei Heptares) and Veld Pharmaceuticals – WODA now provides access to [...]
SAB Biotherapeutics to Present at INNODIA Annual Meeting
08/04/2024
MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is [...]
Kraig Biocraft Laboratories Signs Landmark Agreement in Vietnam's Silk Production Capital
08/04/2024
ANN ARBOR, Mich., April 08, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that it has signed a landmark agreement with the Vietnam Sericulture [...]
Samsung Bioepis Releases Second Quarter 2024 US Biosimilar Market Report
08/04/2024
The 5 th edition explores some IRA implications on biosimilars along with latest price trends, biosimilars market share Marks one year of providing quarterly updates on US biosimilar market trends INCHEON, Korea, April [...]
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
08/04/2024
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11 th Global Summit on Hematologic Malignancies in Whistler, BC, Canada Study participants [...]
Renalytix Announces Financing with Expected Size of up to $4 Million
08/04/2024
LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0 [...]
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
08/04/2024
Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74 BELTSVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company [...]
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
08/04/2024
New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR’s late-breaking poster session Nello Mainolfi, Founder, President and CEO of Kymera, [...]
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
08/04/2024
Howard N. Langstein, MD, FACS joins innovative MedTech company to leverage his vast experience to help other surgeons optimize clinical outcomes in plastic and reconstructive surgery MALVERN, Pa., April 08, 2024 (GLOBE [...]
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
08/04/2024
Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024 and a potential NDA to the FDA in 2025 Continuing to advance [...]
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024
08/04/2024
-- State-of-the-art neoantigen prediction platform (EDGE ™ ) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive performance of HLA [...]
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method
08/04/2024
Pluri’s patent enables mass-scale production of immune cell therapies New patented technology is applicable for the expansion of a variety of immune cells Technology sets stage for potential immune cell therapy [...]
XORTX Announces Participation in Spring 2024 Investor Conferences
08/04/2024
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ ), a late-stage clinical pharmaceutical company focused on [...]
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
08/04/2024
MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, [...]
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
08/04/2024
- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study highlights stroke as [...]
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
08/04/2024
OCS-01 positive results in the first Phase 3 OPTIMIZE-1 trial were presented at the American Society of Cataract and Refractive Surgery (ASCRS) while topline readout from the second Phase 3 OPTIMIZE-2 is anticipated [...]
OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann
08/04/2024
PRESS RELEASE OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann Oxford, United Kingdom – 8 th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology [...]
Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint With Agreement to Acquire Eczacibaşi-Monrol
08/04/2024
The proposed acquisition of Eczacıbaşı-Monrol will: Build on existing partnership in Lu-177 creating a leading manufacturer of the isotope Add 12 PET sites to Curium’s existing network in geographies where Curium is not [...]

Pages